Veritas In Silico Inc. (130A) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Veritas In Silico Inc. (130A:JPX), powered by AI.

Current Price
¥412
Sector
Healthcare
What is the Veritas In Silico Inc. stock price forecast?

Veritas In Silico Inc. is currently trading at ¥412. View real-time AI analysis on Alpha Lenz.

What is Veritas In Silico Inc. insider trading activity?

View the latest insider trading data for Veritas In Silico Inc. on Alpha Lenz.

What is Veritas In Silico Inc.'s P/E ratio?

View Veritas In Silico Inc.'s valuation metrics on Alpha Lenz.

Veritas In Silico Inc.

JPX · 130A
¥412-2(-0.48%)Market closedJPX regular session 09:00–15:00 JST
Ask about Veritas In Silico Inc.'s future dividend policy...
Alpha Chat Insight

Veritas In Silico Inc.'s ROE is -21.3%. Explore profitability and growth together.

Ask for details

Company Overview

Veritas In Silico Inc. is a pioneering company within the biotechnology sector, utilizing cutting-edge computational techniques to advance drug discovery processes. At its core, Veritas In Silico focuses on leveraging artificial intelligence and machine learning to simulate and predict molecular interactions, thereby accelerating the timeline from research to drug development. By employing in silico methods, the company aims to reduce the reliance on traditional laboratory settings, promoting faster and more cost-effective solutions in the pharmaceutical industry. Notable for its innovative approach, Veritas In Silico serves as a crucial player in the push for digital transformation within the biomedical research field. This transformation is particularly significant for pharmaceutical companies seeking efficient discovery pathways and improved accuracy in drug target identification. The company's infrastructure supports collaborations with global pharmaceutical firms and academic institutions, driving advancements in the treatment of complex diseases and enhancing precision medicine efforts. In the financial markets, Veritas In Silico incites interest for its potential to redefine drug discovery paradigms, making it a central component in the conversation around the future of biotech innovation and computational solutions.

CEOMr. Shingo Nakamura
SectorHealthcare
IndustryBiotechnology
0

Company Statistics

FY 2025

Profile

N/AMarket Cap
¥91,140,000Revenue
0.00Shares Out
0Employees

Margins

N/AGross
-383.51%EBITDA
-435.32%Operating
-462.96%Pre-Tax
-467.05%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

-20.12%Rev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-20.59%ROA
-21.32%ROE
-19.20%ROIC

Financial Health

¥1,825,213,000Cash & Cash Equivalents
¥-1,724,177,000Net Debt
5.66%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Veritas In Silico Inc. (ticker: 130A) is a company listed on JPX in the Healthcare sector (Biotechnology).

The current price is 412 with a P/E ratio of -x and P/B of -x.

ROE is -21.32% and operating margin is -435.32%. Annual revenue is $91M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Veritas In Silico Inc. (130A) Stock Forecast 2026 ¥412 — Price, Financials & Analyst Targets | Alpha Lenz